{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:16:31Z","timestamp":1786990591892,"version":"build-2736575974"},"reference-count":57,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100011927","name":"European Society of Gastrointestinal Endoscopy","doi-asserted-by":"publisher","award":["GOG-0218"],"award-info":[{"award-number":["GOG-0218"]}],"id":[{"id":"10.13039\/501100011927","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011925","name":"European Society of\u00a0Human Reproduction and Embryology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.ijgc.2025.101671","type":"journal-article","created":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T16:49:14Z","timestamp":1738255754000},"page":"101671","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Controversies in the management of grade 1 and 2 endometrioid carcinoma of the ovary and uterus"],"prefix":"10.1016","volume":"35","author":[{"given":"Alice","family":"Bergamini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina Chiara","family":"Cecere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Bartoletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Musacchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandro","family":"Pignata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ijgc.2025.101671_bib1","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.pathol.2023.01.003","article-title":"The diverse morphology and immunophenotype of ovarian endometrioid carcinomas","volume":"55","author":"Talia","year":"2023","journal-title":"Pathology"},{"issue":"1","key":"10.1016\/j.ijgc.2025.101671_bib2","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jogc.2016.10.006","article-title":"Endometrioid carcinoma of the ovary: outcomes compared to serous carcinoma after 10 years of follow-up","volume":"39","author":"Bouchard-Fortier","year":"2017","journal-title":"J Obstet Gynaecol Can"},{"issue":"1","key":"10.1016\/j.ijgc.2025.101671_bib3","doi-asserted-by":"crossref","first-page":"4995","DOI":"10.1038\/s41467-020-18819-5","article-title":"Molecular stratification of endometrioid ovarian carcinoma predicts clinical outcome","volume":"11","author":"Hollis","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.ijgc.2025.101671_bib4","article-title":"Molecular classification grade 3 endometrial endometrioid carcinoma using a next-generation sequencing-based gene panel","volume":"12","author":"Li","year":"2022","journal-title":"Front Oncol"},{"issue":"22","key":"10.1016\/j.ijgc.2025.101671_bib5","doi-asserted-by":"crossref","first-page":"5732","DOI":"10.3390\/ijms20225732","article-title":"Mutation-driven signals of ARID1A and PI3K pathways in ovarian carcinomas: alteration is an opportunity","volume":"20","author":"De","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.ijgc.2025.101671_bib6","doi-asserted-by":"crossref","first-page":"515","DOI":"10.3390\/ijms18030515","article-title":"Association of hormone receptor expression with survival in ovarian endometrioid carcinoma: biological validation and clinical implications","volume":"18","author":"Rambau","year":"2017","journal-title":"Int J Mol Sci"},{"issue":"9","key":"10.1016\/j.ijgc.2025.101671_bib7","doi-asserted-by":"crossref","first-page":"e420","DOI":"10.1016\/S1470-2045(24)00192-X","article-title":"Clinical research in endometrial cancer: consensus recommendations from the Gynecologic Cancer Intergroup","volume":"25","author":"Creutzberg","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijgc.2025.101671_bib8","article-title":"A review of the clinical characteristics and novel molecular subtypes of endometrioid ovarian cancer","volume":"11","author":"Chen","year":"2021","journal-title":"Front Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2025.101671_bib9","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1002\/ijc.32907","article-title":"Molecular profiling identifies synchronous endometrial and ovarian cancers as metastatic endometrial cancer with favorable clinical outcome","volume":"147","author":"Reijnen","year":"2020","journal-title":"Int J Cancer"},{"issue":"3","key":"10.1016\/j.ijgc.2025.101671_bib10","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.annonc.2023.11.015","article-title":"ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease","volume":"35","author":"Ledermann","year":"2024","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.ijgc.2025.101671_bib11","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1136\/ijgc-2022-003560","article-title":"Oncologic and pregnancy outcomes after fertility-sparing surgery for stage I, low-grade endometrioid ovarian cancer","volume":"32","author":"Swift","year":"2022","journal-title":"Int J Gynecol Cancer"},{"issue":"11","key":"10.1016\/j.ijgc.2025.101671_bib12","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1093\/annonc\/mdw311","article-title":"Fertility-sparing surgery in epithelial ovarian cancer: a systematic review of oncological issues","volume":"27","author":"Bentivegna","year":"2016","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.ijgc.2025.101671_bib13","doi-asserted-by":"crossref","first-page":"e602","DOI":"10.1016\/S1470-2045(24)00262-6","article-title":"Fertility-sparing treatment and follow-up in patients with cervical cancer, ovarian cancer, and borderline ovarian tumours: guidelines from ESGO, ESHRE, and ESGE","volume":"25","author":"Morice","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijgc.2025.101671_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113398","article-title":"Lymph node staging in grade 1\u20132 endometrioid ovarian carcinoma apparently confined to the ovary: is it worth?","volume":"195","author":"Bizzarri","year":"2023","journal-title":"Eur J Cancer"},{"issue":"10","key":"10.1016\/j.ijgc.2025.101671_bib15","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.annonc.2023.07.011","article-title":"Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Gonz\u00e1lez-Mart\u00edn","year":"2023","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2025.101671_bib16","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1002\/path.2659","article-title":"Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma","volume":"220","author":"Madore","year":"2010","journal-title":"J Pathol"},{"key":"10.1016\/j.ijgc.2025.101671_bib17","series-title":"Ovarian Cancer\/Fallopian Tube Cancer\/Primary Peritoneal Cancer - Guidelines Detail","year":"2024"},{"issue":"6","key":"10.1016\/j.ijgc.2025.101671_bib18","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3747\/co.v17i6.676","article-title":"Endometrioid ovarian carcinoma benefits from aromatase inhibitors: case report and literature review","volume":"17","author":"Pan","year":"2010","journal-title":"Curr Oncol"},{"issue":"26","key":"10.1016\/j.ijgc.2025.101671_bib19","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N Engl J Med."},{"issue":"25","key":"10.1016\/j.ijgc.2025.101671_bib20","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus bevacizumab as first-line maintenance in ovarian cancer","volume":"381","author":"Ray-Coquard","year":"2019","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.ijgc.2025.101671_bib21","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer","volume":"381","author":"Gonz\u00e1lez-Mart\u00edn","year":"2019","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ijgc.2025.101671_bib22","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.ygyno.2014.01.027","article-title":"Prognostic and predictive value of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) score in surgery for recurrent ovarian cancer","volume":"132","author":"Harter","year":"2014","journal-title":"Gynecol Oncol"},{"issue":"10106","key":"10.1016\/j.ijgc.2025.101671_bib23","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Coleman","year":"2017","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ijgc.2025.101671_bib24","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.ygyno.2019.06.011","article-title":"PARAGON: a phase II study of anastrozole in patients with estrogen receptor-positive recurrent\/metastatic low-grade ovarian cancers and serous borderline ovarian tumors","volume":"154","author":"Tang","year":"2019","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2025.101671_bib25","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.ygyno.2009.01.012","article-title":"A phase II study of fulvestrant in the treatment of multiply-recurrent epithelial ovarian cancer","volume":"113","author":"Argenta","year":"2009","journal-title":"Gynecol Oncol"},{"issue":"5","key":"10.1016\/j.ijgc.2025.101671_bib26","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2020-000926","article-title":"Phase II trial of ribociclib and letrozole in patients with relapsed oestrogen receptor-positive ovarian or endometrial cancers","volume":"5","author":"Colon-Otero","year":"2020","journal-title":"ESMO Open"},{"issue":"10","key":"10.1016\/j.ijgc.2025.101671_bib27","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.3390\/cancers16101862","article-title":"Novel endocrine therapeutic opportunities for estrogen receptor-positive ovarian cancer-what can we learn from breast cancer?","volume":"16","author":"Ottenbourgs","year":"2024","journal-title":"Cancers"},{"issue":"suppl 3","key":"10.1016\/j.ijgc.2025.101671_bib28","first-page":"A24","article-title":"Clinical outcomes with trastuzumab emtansine or ipatasertib plus paclitaxel for persistent\/recurrent rare epithelial ovarian carcinomas: ENGOT-GYN2\/GOG-3051\/BOUQUET phase 2 biomarker-directed study","volume":"34","author":"Gershenson","year":"2024","journal-title":"Int J Gynecol Cancer"},{"issue":"3","key":"10.1016\/j.ijgc.2025.101671_bib29","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1053\/j.semdp.2022.02.002","article-title":"Low grade endometrial endometrioid adenocarcinoma: a review and update with emphasis on morphologic variants, mimics, immunohistochemical and molecular features","volume":"39","author":"Lucas","year":"2022","journal-title":"Semin Diagn Pathol"},{"issue":"2","key":"10.1016\/j.ijgc.2025.101671_bib30","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.ygyno.2008.10.019","article-title":"Endometrioid uterine cancer: histopathological risk factors of local and distant recurrence","volume":"112","author":"Fujimoto","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ijgc.2025.101671_bib31","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ygyno.2022.11.012","article-title":"Recurrence and survival in endometrioid endometrial cancer - a population-based cohort study","volume":"168","author":"\u00c5kesson","year":"2023","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2025.101671_bib32","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.ygyno.2007.03.042","article-title":"Relationship of estrogen and progesterone receptors to clinical outcome in metastatic endometrial carcinoma: a Gynecologic Oncology Group Study","volume":"106","author":"Singh","year":"2007","journal-title":"Gynecol Oncol"},{"issue":"9","key":"10.1016\/j.ijgc.2025.101671_bib33","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.annonc.2022.05.009","article-title":"Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Oaknin","year":"2022","journal-title":"Ann Oncol"},{"issue":"16","key":"10.1016\/j.ijgc.2025.101671_bib34","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1158\/1078-0432.CCR-15-2878","article-title":"Improved risk assessment by integrating molecular and clinicopathological factors in early-stage endometrial cancer-combined analysis of the PORTEC cohorts","volume":"22","author":"Stelloo","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijgc.2025.101671_bib35","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ygyno.2024.10.028","article-title":"Hormonal biomarkers remain prognostically relevant within the molecular subgroups in endometrial cancer","volume":"192","author":"Vrede","year":"2025","journal-title":"Gynecol Oncol"},{"issue":"11","key":"10.1016\/j.ijgc.2025.101671_bib36","doi-asserted-by":"crossref","first-page":"3695","DOI":"10.1245\/s10434-015-4443-1","article-title":"Microscopic omental metastasis in clinical Stage I endometrial cancer: a meta-analysis","volume":"22","author":"Joo","year":"2015","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2025.101671_bib37","doi-asserted-by":"crossref","first-page":"3","DOI":"10.52054\/FVVO.15.1.065","article-title":"ESGO\/ESHRE\/ESGE Guidelines for the fertility-sparing treatment of patients with endometrial carcinoma","volume":"15","author":"Rodolakis","year":"2023","journal-title":"Facts Views Vis Obgyn"},{"issue":"3","key":"10.1016\/j.ijgc.2025.101671_bib38","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S1470-2045(18)30079-2","article-title":"Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial","volume":"19","author":"De Boer","year":"2018","journal-title":"Lancet Oncol"},{"issue":"24","key":"10.1016\/j.ijgc.2025.101671_bib39","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1056\/NEJMoa1813181","article-title":"Adjuvant chemotherapy plus radiation for locally advanced endometrial cancer","volume":"380","author":"Matei","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ijgc.2025.101671_bib40","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/ijgo.14923","article-title":"FIGO staging of endometrial cancer: 2023","volume":"162","author":"Berek","year":"2023","journal-title":"Int J Gynecol Obstet"},{"issue":"21","key":"10.1016\/j.ijgc.2025.101671_bib41","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1200\/JCO.18.01575","article-title":"Phase III trial: adjuvant pelvic radiation therapy versus vaginal brachytherapy plus paclitaxel\/carboplatin in high-intermediate and high-risk early stage endometrial cancer","volume":"37","author":"Randall","year":"2019","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2025.101671_bib42","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1200\/JCO-24-01887","article-title":"Pembrolizumab or placebo plus adjuvant chemotherapy with or without radiotherapy for newly diagnosed, high-risk endometrial cancer: results in mismatch repair-deficient tumors","volume":"43","author":"Slomovitz","year":"2025","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.ijgc.2025.101671_bib43","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1136\/ijgc-2020-001929","article-title":"PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer","volume":"30","author":"van den Heerik","year":"2020","journal-title":"Int J Gynecol Cancer"},{"issue":"23","key":"10.1016\/j.ijgc.2025.101671_bib44","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1056\/NEJMoa2216334","article-title":"Dostarlimab for primary advanced or recurrent endometrial cancer","volume":"388","author":"Mirza","year":"2023","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.ijgc.2025.101671_bib45","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa2302312","article-title":"Pembrolizumab plus chemotherapy in advanced endometrial cancer","volume":"388","author":"Eskander","year":"2023","journal-title":"N Engl J Med."},{"issue":"1","key":"10.1016\/j.ijgc.2025.101671_bib46","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ygyno.2007.04.032","article-title":"The relationship between Histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a gynecologic oncology group study","volume":"106","author":"McMeekin","year":"2007","journal-title":"Gynecol Oncol"},{"issue":"33","key":"10.1016\/j.ijgc.2025.101671_bib47","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.1200\/JCO.20.01076","article-title":"Carboplatin and paclitaxel for advanced endometrial cancer: final overall survival and adverse event analysis of a phase III trial (NRG oncology\/Gog0209)","volume":"38","author":"Miller","year":"2020","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2025.101671_bib48","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ygyno.2019.05.007","article-title":"Phase 2 study of anastrozole in recurrent estrogen (ER)\/progesterone (PR) positive endometrial cancer: the Paragon trial - ANZGOG 0903","volume":"154","author":"Mileshkin","year":"2019","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2025.101671_bib49","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ygyno.2003.11.008","article-title":"Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a gynecologic oncology group study","volume":"92","author":"Fiorica","year":"2004","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2025.101671_bib50","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ygyno.2003.09.018","article-title":"Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a gynecologic oncology group study","volume":"92","author":"Whitney","year":"2004","journal-title":"Gynecol Oncol"},{"issue":"8","key":"10.1016\/j.ijgc.2025.101671_bib51","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1200\/JCO.2014.58.3401","article-title":"Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma","volume":"33","author":"Slomovitz","year":"2015","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ijgc.2025.101671_bib52","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1001\/jamaoncol.2022.1047","article-title":"Safety and efficacy of the mTOR inhibitor, Vistusertib, combined with anastrozole in patients with hormone receptor-positive recurrent or metastatic endometrial cancer: the VICTORIA multicenter, open-label, phase 1\/2 randomized clinical trial","volume":"8","author":"Heudel","year":"2022","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2025.101671_bib53","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1200\/JCO.22.00628","article-title":"A phase II, two-stage study of letrozole and Abemaciclib in estrogen receptor-positive recurrent endometrial cancer","volume":"41","author":"Konstantinopoulos","year":"2023","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ijgc.2025.101671_bib54","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1056\/NEJMoa2108330","article-title":"Lenvatinib plus pembrolizumab for advanced endometrial cancer","volume":"386","author":"Makker","year":"2022","journal-title":"N Engl J Med"},{"issue":"35","key":"10.1016\/j.ijgc.2025.101671_bib55","doi-asserted-by":"crossref","first-page":"5400","DOI":"10.1200\/JCO.22.02906","article-title":"Oral selinexor as maintenance therapy after first-line chemotherapy for advanced or recurrent endometrial cancer","volume":"41","author":"Vergote","year":"2023","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ijgc.2025.101671_bib56","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1136\/ijgc-2024-005412","volume":"34","author":"Vergote","year":"2024","journal-title":"Int J Gynecol Cancer"},{"issue":"suppl 16","key":"10.1016\/j.ijgc.2025.101671_bib57","article-title":"Dose-expansion part of a phase 1b global study of E7386 in combination with lenvatinib (LEN) in patients (pts) with hepatocellular carcinoma (HCC) and other solid tumors including endometrial cancer (EC)","volume":"42","author":"Lee","year":"2024","journal-title":"J Clin Oncol"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X25001963?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X25001963?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T01:40:04Z","timestamp":1772329204000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X25001963"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":57,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S1048891X25001963"],"URL":"https:\/\/doi.org\/10.1016\/j.ijgc.2025.101671","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Controversies in the management of grade 1 and 2 endometrioid carcinoma of the ovary and uterus","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijgc.2025.101671","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc. on behalf of European Society of Gynaecological Oncology and the International Gynecologic Cancer Society.","name":"copyright","label":"Copyright"}],"article-number":"101671"}}